Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually. The lecanemab data and additional research findings from Eis
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD congress finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
- Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI has been approved in China as a treatment of mild cognitive.
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.